GlassScriptPhysician profile
Janus J Kulpa
NPI 1891833828
$2,844.14
in general payments reported to CMS, 2019-2025
28 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $713 · 2021: $493 · 2022: $477 · 2023: $259 · 2024: $212 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $518.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $453.28 | 2019-2022 | |
| Lilly USA, LLC | $402.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $318.84 | 2021-2025 | |
| Amarin Pharma, INC. | $157.25 | 2020 | |
| Novo Nordisk INC | $154.55 | 2019-2024 | |
| Glaxosmithkline, LLC. | $93.26 | 2020-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $76.49 | 2020-2021 | |
| Amgen INC. | $70.67 | 2022-2025 | Evenity |
| Sumitomo Pharma America, INC. | $68.82 | 2024 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $56.47 | 2020-2021 | |
| Horizon Therapeutics Plc | $51.05 | 2019-2022 | |
| Corcept Therapeutics | $48.21 | 2021 | |
| Xeris Pharmaceuticals, INC. | $45.14 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $41.38 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.24 | 2023 | |
| Allergan, INC. | $37.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.14 | 2022-2023 | Spravato |
| Exact Sciences Corporation | $28.21 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $26.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.44 | 2022 | |
| Angiodynamics, INC. | $19.26 | 2019 | |
| Endo Pharmaceuticals INC. | $17.47 | 2020 | |
| Renalytix Ai, INC. | $17.12 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $14.59 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $13.21 | 2024 | Horizant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.48 | 2021 | |
| Dexcom, INC. | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janus Kulpa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.